# China Human Genetics Market > China Human Genetics Market Research Report By Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment) andBy Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.82% - **2024:** $ 2,225.23 Million - **2025:** $ 2,466 Million - **2035:** $ 6,887.01 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), QIAGEN (DE), Myriad Genetics (US), BGI Genomics (CN), Genomatix (DE), PerkinElmer (US) **Report ID:** MRFR/LS/47569-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-human-genetics-market-49319 --- ## Market Summary ## **China Human Genetics Market Overview** As per MRFR analysis, the China Human Genetics Market Size was estimated at $1.72 billion in 2023. The China Human Genetics Market is expected to grow from $1.91 billion in 2024 to $11.53 billion by 2035. The China Human Genetics Market CAGR (growth rate) is expected to be around 17.772% during the forecast period (2025 - 2035). ### **Key China Human Genetics Market Trends Highlighted** The market for human genetics in China is expanding significantly due to rising government funding for genetic research and medical developments. The Chinese government has taken steps to advance biotechnology, especially in the field of genomics, which has improved the capacities of regional research organizations and businesses. Another significant market driver is the trend toward customized medicine, as China seeks to enhance healthcare results by using individualized treatment regimens. The need for genetic testing and diagnosis is increasing due to a large population and growing knowledge of genetic illnesses. In order to improve disease management and prediction, recent trends show an increasing interest in integrating genetic data into healthcare systems. Furthermore, there is a discernible trend toward non-invasive carrier screening and prenatal testing, which reflects the public's desire for easily accessible genetic services. The developments in gene editing and CRISPR technology also point to a growing field in which genetic modification may be used to cure a number of inherited diseases. Partnerships between academic institutions, IT companies, and healthcare providers to create novel genetic treatments further increase the opportunities in the China human genetics market. New market entrants may investigate specialized fields like gene therapy and synthetic biology as the regulatory environment surrounding genetic research and application continues to change. China is positioned as a growing center for genetic research and its applications due to the growing corporate and public sector investment in health technology, opening the door for developments that could benefit millions of people's health. ## Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **China Human Genetics Market Drivers** ### **Increasing Prevalence of Genetic Disorders** The rising prevalence of genetic disorders in China is a significant driver for the China Human Genetics Market. According to the National Health Commission of China, genetic disorders are prevalent in about 1 in 1,000 individuals, leading to over 50,000 newborns annually affected by congenital disorders. As the Chinese population ages and with advancements in prenatal genetic testing, the need for genetic solutions is propelling market growth. Established organizations like the Chinese Academy of Sciences have intensified Research and Development efforts in this area, focusing on innovative genetic therapies and diagnostic tools that cater specifically to the needs of the Chinese demographic. This ongoing commitment from the government and private entities aims to reduce diagnostic delays and improve treatment outcomes for affected individuals, thereby continually expanding the China Human Genetics Market. ### **Government Initiatives and Funding** The Chinese government has implemented various initiatives to stimulate the growth of the genetics sector, significantly influencing the China Human Genetics Market. The 13th Five-Year Plan emphasizes the importance of biotechnology, with a focus on personalized medicine and genetic research. The government has allocated approximately USD 1.5 billion for genomics and genetics-related Research and Development under this plan. Leading organizations such as the National Natural Science Foundation of China are actively funding research projects, facilitating collaborations between academic institutions and private sectors. This increased financial support is crucial for developing new technologies in genetic testing and therapies, ensuring that the China Human Genetics Market continues on its upward trajectory. ### **Growing Demand for Personalized Medicine** Personalized medicine is gaining traction in China, driven by a growing awareness of its benefits among healthcare providers and patients. According to data from the China National Cancer Center, there has been a 25% increase in the adoption of personalized treatment plans for cancer patients over the last three years. Organizations such as the China Precision Medicine Initiative are at the forefront, promoting the integration of genetic testing into routine health assessments. As healthcare continues to evolve towards more tailored healthcare solutions, the demand for genetic diagnostics and related tools is expected to skyrocket, driving growth within the China Human Genetics Market. ### **Technological Advancements in Genetic Testing** The rapid advancements in genetic testing technologies are playing an essential role in expanding the China Human Genetics Market. Innovations such as next-generation sequencing and CRISPR technology have drastically improved both the speed and accuracy of genetic tests. For instance, the introduction of next-generation sequencing has reduced the time for genetic testing from weeks to mere hours. The Ministry of Science and Technology in China supports these developments, encouraging private enterprises and academic partnerships to enhance genetic testing capabilities. Companies like BGI Group are leading advancements in this space, creating accessible and affordable DNA testing solutions. As these technologies become more integrated into clinical practices, market growth is anticipated to accelerate significantly. ## **China Human Genetics Market Segment Insights** ### **Human Genetics Market Application Insights** The China Human Genetics Market is witnessing a notable evolution in its Application segment, driven by advancements in genetic technology and a growing awareness of personalized health solutions. The rising trend of Wellness and E-Commerce reflects a societal shift towards preventive health measures, with individuals increasingly seeking genetic tests to inform lifestyle choices and enhance overall well-being. Meanwhile, Preventive Medicine is becoming a critical focus within this market, as genetic testing empowers healthcare professionals and consumers to mitigate risks for hereditary diseases, ultimately fostering healthier populations. Diagnostic and Treatment applications are also gaining traction, with genetic insights playing a pivotal role in tailoring treatment plans. This personalization not only enhances patient outcomes but also streamlines healthcare processes in China's extensive healthcare system. The significance of these applications in the human genetics domain cannot be understated, as they serve as a cornerstone for health innovation, guiding effective interventions and supporting a burgeoning health-conscious culture in China. As the country addresses its unique health challenges, these segments represent a substantial opportunity for growth, reflecting the increasing demand for precision medicine solutions that effectively cater to the needs of its vast population. Overall, the Application segment of the China Human Genetics Market stands as a vital component that intertwines with broader trends in healthcare, technology, and consumer behavior, indicating a capacity for sustained development. ## Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Human Genetics Market Test Insights** The Test segment of the China [Human Genetics Market](../../../reports/human-genetics-market-714) plays a pivotal role in the country's healthcare landscape, striving to meet the rising demand for personalized medicine and genetic insights. The segment encompasses various types of testing, including Non-Invasive Prenatal Testing (NIPT), which has gained considerable traction due to its accuracy and safety in prenatal screening, making it a preferred choice among expectant mothers. Carrier testing is also significant as it identifies individuals who may carry gene mutations for inheritable genetic disorders, aiding in informed family planning decisions. Pharmacogenomic testing is gaining importance as it allows healthcare professionals to tailor medication based on a person's genetic makeup, enhancing therapeutic efficacy and reducing adverse effects. Karyotype testing, which evaluates chromosomal abnormalities, and thrombophilia testing, focused on blood clotting disorders, further demonstrate the breadth of genetic testing available within this segment. Moreover, Septin 9 Biomarker Testing is crucial for early detection of certain cancers, while Next Generation Sequencing (NGS) represents a cutting-edge approach that allows for comprehensive genomic analysis, contributing to advancements in disease diagnosis and treatment. Collectively, these testing methodologies underscore the dynamic shifts within the China Human Genetics Market, driven by technological innovation and an increasing focus on precision medicine. ## **China Human Genetics Market Key Players and Competitive Insights** The China Human Genetics Market has witnessed substantial growth, characterized by intense competition among key players. With increasing investments in advanced technologies, proprietary research, and the pursuit of genetic-based solutions for healthcare, the landscape is dynamic and evolving. The market's expansion is fueled by rising incidences of genetic disorders and an increased public awareness of personalized medicine. As the demand for genetic testing and genomics rises, the industry has seen collaborations between biotechnology firms, research institutions, and healthcare providers aimed at driving innovation and improving patient outcomes. Overall, the competitive insights reveal a landscape that thrives on technological advancements, regulatory frameworks, and an emphasis on precision medicine tailored to the unique genetic needs of the Chinese population. Huada Technology has established a formidable presence in the China Human Genetics Market, positioning itself as a leader in genomic services and solutions. The company's extensive experience in next-generation sequencing technology has allowed it to develop various applications in healthcare, agriculture, and research. Huada Technology is noted for its rapid turnaround times and comprehensive data analysis, making it an attractive option for researchers and clinicians alike. Its collaborations with universities and research institutions foster innovation and extend its service offerings. The company has made significant strides in enhancing genetic testing processes, making it easier for healthcare providers to adopt genomic solutions in their practice. Furthermore, Huada Technology has committed to leveraging its technological strengths to drive further advancements in the market. Fudan University has a strong influence on the China Human Genetics Market through its focused research and academic contributions. Renowned for its rigorous academic programs and research initiatives, Fudan University plays a pivotal role in advancing human genetics studies through key products and services related to genomic research, diagnostics, and data analysis. The university is actively involved in various research projects, collaborating with both public and private sectors to push the boundaries of genetic understanding. While its primary function is educational, the commercialization of its research outcomes has led to significant advancements in genetic testing and therapeutic interventions within China. Fudan University has also been part of strategic partnerships and mergers that enhance its research capabilities, further cementing its role in shaping the future of human genetics in the region. Its commitment to innovation and collaboration underpins the university's strengths in fostering a vibrant ecosystem for human genetics that responds to the evolving needs of society. ### **Key Companies in the China Human Genetics Market Include** - Huada Technology - Fudan University - **[Novogene](https://www.novogene.com/us-en/services/research-services/genome-sequencing/whole-genome-sequencing/human-whole-genome-sequencing/)** - Sangamo Therapeutics - WuXi AppTec - Beijing Genomics Institute - Chengdu Tianyi - Zhongshan Hospital - Zhejiang University - GeneTech - Huanghe Genetic - Guangdong Haoyuan Bio - Shanghai Genomics - BGI Group - Qiagen ### **China Human Genetics Market Developments** Recent developments in the China Human Genetics Market have showcased significant advancements and shifts in the landscape. Huada Technology has continued to innovate in genetic sequencing technology, enhancing its capabilities that have subsequently drawn interest from various sectors. Fudan University is collaborating with biopharmaceutical firms to advance Research and Development in personalized medicine, reflecting a growth trend in tailored healthcare solutions. In terms of significant corporate activity, a notable merger occurred in May 2023 when the Beijing Genomics Institute acquired a majority stake in a biotech firm, thus reinforcing its position in the market. Additionally, growth in the valuation of companies like Novogene and Sangamo Therapeutics is impacting market dynamics, with Novogene reporting a substantial increase in revenue due to heightened demand for genetic testing services. Furthermore, WuXi AppTec is ramping up its biomanufacturing capabilities to meet the increasing need for gene therapies. Over the past 2-3 years, investment in genetic technologies has surged, particularly following government initiatives aimed at advancing life sciences and biotechnology sectors, further solidifying China's role as a leader in the global human genetics arena. ## **China Human Genetics Market Segmentation Insights** ### **Human Genetics Market Application Outlook** - Wellness & E-Commerce - Preventive Medicine - Diagnostic & Treatment ### **Human Genetics Market Test Outlook** - NIPT - Carrier Testing - Pharmacogenomic Testing - Karyotype Testing - Thrombophilia Testing - Septin 9 Biomarker Testing - NGS ## Market Drivers ### Growing Public Awareness and Education Public awareness regarding genetic health is steadily increasing in China, significantly impacting the human genetics market. Educational campaigns and initiatives by healthcare organizations are informing the population about the benefits of genetic testing and personalized medicine. This heightened awareness is leading to a greater acceptance of genetic services, with more individuals seeking testing for predispositions to various diseases. As a result, the market is experiencing a notable uptick in demand, with estimates suggesting a growth of around 20% in the number of genetic tests conducted annually. This trend indicates a shift towards proactive health management, further solidifying the role of genetics in healthcare. ### Regulatory Support for Genetic Services The regulatory landscape in China is evolving to support the human genetics market. Recent policy changes have streamlined the approval processes for genetic testing services and therapies, encouraging innovation and investment in the sector. The government is actively promoting genetic research and its applications in healthcare, which is likely to enhance the market's growth prospects. With a focus on establishing ethical guidelines and quality standards, the regulatory framework aims to ensure the safety and efficacy of genetic services. This supportive environment is expected to attract both domestic and international players, potentially increasing market competition and driving advancements in genetic technologies. ### Increasing Prevalence of Genetic Disorders The rising incidence of genetic disorders in China is a crucial driver for the human genetics market. With an estimated 1 in 10 individuals affected by some form of genetic condition, the demand for genetic testing and counseling services is surging. This trend is further supported by the increasing awareness of hereditary diseases among the population. As healthcare providers and patients seek to understand genetic risks, the human genetics market is likely to expand significantly. The Chinese government has also recognized this issue, allocating resources to improve genetic healthcare services. This focus on addressing genetic disorders is expected to propel the market forward, with projections indicating a potential growth rate of over 15% annually in the coming years. ### Technological Innovations in Genetic Research Technological advancements in genetic research are transforming the human genetics market in China. Innovations such as next-generation sequencing (NGS) and CRISPR gene editing are enhancing the accuracy and efficiency of genetic testing. These technologies enable researchers and clinicians to identify genetic mutations more effectively, leading to better diagnostic and therapeutic options. The Chinese market is witnessing a surge in investments in biotechnology firms that specialize in these cutting-edge technologies. As a result, the human genetics market is projected to reach a valuation of approximately $10 billion by 2027, driven by the increasing adoption of these advanced tools in clinical settings. ### Integration of Genetics into Personalized Medicine The integration of genetics into personalized medicine is emerging as a pivotal driver for the human genetics market in China. As healthcare shifts towards tailored treatment approaches, genetic information is becoming essential for developing individualized therapies. This trend is particularly evident in oncology, where genetic profiling is used to determine the most effective treatment plans for cancer patients. The human genetics market is likely to benefit from this integration, with projections indicating a substantial increase in the demand for genetic testing services. By 2026, the market could see a growth rate of approximately 18%, reflecting the increasing reliance on genetic insights to inform clinical decisions. ## Future Outlook The [Human Genetics Market](https://www.marketresearchfuture.com/reports/human-genetics-market-714) in China is projected to grow at a 10.82% CAGR from 2025 to 2035, driven by advancements in genomic technologies, increasing healthcare investments, and rising demand for personalized medicine. **New opportunities:** - Development of AI-driven genetic analysis platforms for precision medicine. - Expansion of direct-to-consumer genetic testing services targeting health and ancestry. - Partnerships with biotech firms for innovative gene therapy solutions. By 2035, the human genetics market is expected to achieve substantial growth, driven by technological advancements and increased consumer demand. ## Segment Insights ### By Application: Wellness & E-Commerce (Largest) vs. Preventive Medicine (Fastest-Growing) In the China human genetics market, the application segment showcases a competitive landscape with Wellness & E-Commerce emerging as the largest segment by a significant margin. This dominant segment reflects an increasing consumer preference for personalized genetic insights related to wellness products and services. Meanwhile, Preventive Medicine is gaining traction, appealing to healthcare providers and individuals alike who are increasingly focused on preventive healthcare measures based on genetic predispositions. Growth in this segment is strongly driven by rising health awareness and technological advancements in genetic testing. Factors such as an aging population and an increase in genetic diseases have accentuated the demand for preventive solutions. The evolving landscape of e-commerce continues to facilitate the accessibility of genetic services, enhancing consumer engagement and encouraging innovation within the market. Wellness & E-Commerce: Dominant vs. Preventive Medicine: Emerging Wellness & E-Commerce is marked by its strong presence in consumer markets, where genetic testing is integrated into health and wellness solutions. This segment is characterized by innovative approaches to genetic profiling, enabling consumers to access personalized guidance based on their genetic data. The shift towards e-commerce platforms has made these services more accessible, driving growth and consumer adoption. Conversely, Preventive Medicine is viewed as an emerging segment, increasingly supported by healthcare institutions looking to mitigate health risks through genetic insights. This sector focuses on early intervention strategies, turning genetic data into actionable health plans. Both segments demonstrate unique strengths, with Wellness & E-Commerce leading in market share while Preventive Medicine showcases rapid growth potential. ### By Test: NIPT (Largest) vs. NGS (Fastest-Growing) The market share distribution among the various testing segments in the China human genetics market illustrates a dynamic environment. Currently, Non-Invasive Prenatal Testing (NIPT) holds the largest share, driven by its increasing adoption among expectant parents seeking non-invasive options for genetic screening. Carrier Testing and Pharmacogenomic Testing also contribute significantly to the market share, reflecting growing awareness and demand for personalized medicine solutions. In terms of growth trends, Next-Generation Sequencing (NGS) is emerging as the fastest-growing segment in the China human genetics market. The increasing applications of NGS in research and clinical diagnostics, combined with technological advancements, are propelling its adoption. Factors such as rising investments in genetic research and the expansion of genetic testing services are driving growth across all segments, with a notable trend towards integrating these tests into routine healthcare. NIPT (Dominant) vs. NGS (Emerging) NIPT is a dominant player within the China human genetics market, primarily due to its non-invasive nature, which appeals to a wide demographic of expectant parents. The accuracy and efficiency of NIPT in screening for genetic abnormalities make it a preferred choice among healthcare providers and patients alike. On the other hand, NGS is recognized as an emerging segment, rapidly gaining traction due to its ability to provide comprehensive genomic data that is invaluable for personalized medicine. With advancements in technology, NGS is becoming more accessible, which encourages its integration into various healthcare settings. Together, these segments reflect the evolving landscape of genetic testing and the increasing demand for advanced, accurate, and patient-friendly testing solutions. ## Competitive Benchmarking The human genetics market in China is characterized by a dynamic competitive landscape, driven by rapid advancements in genomic technologies and increasing demand for personalized medicine. Key players such as Illumina (US), BGI Genomics (CN), and Roche (CH) are at the forefront, each adopting distinct strategies to enhance their market presence. Illumina (US) focuses on innovation through continuous investment in next-generation sequencing technologies, while BGI Genomics (CN) leverages its extensive local expertise to expand its service offerings in genomic research and diagnostics. Roche (CH), on the other hand, emphasizes strategic partnerships to bolster its capabilities in precision medicine, thereby shaping a competitive environment that is increasingly collaborative and innovation-driven.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with a mix of established players and emerging companies competing for market share. This fragmentation allows for diverse offerings and fosters competition, as key players strive to differentiate themselves through technological advancements and service quality. In October Illumina (US) announced a partnership with a leading Chinese research institution to develop a new genomic sequencing platform tailored for the Asian population. This strategic move is likely to enhance Illumina's market penetration in China, aligning with the growing demand for personalized healthcare solutions. The collaboration underscores the importance of localized approaches in addressing specific genetic variations prevalent in the region. In September BGI Genomics (CN) launched a comprehensive genomic testing service aimed at early disease detection and prevention. This initiative not only positions BGI as a leader in the Chinese market but also reflects a broader trend towards proactive healthcare management. By offering accessible genomic testing, BGI is likely to capture a significant share of the growing consumer base interested in preventive health measures. In August Roche (CH) expanded its portfolio by acquiring a biotechnology firm specializing in CRISPR technology. This acquisition is strategically significant as it enhances Roche's capabilities in gene editing, a field that is rapidly gaining traction in therapeutic applications. The integration of CRISPR technology into Roche's offerings may provide a competitive edge in developing innovative treatments, thereby reinforcing its position in the market. As of November current trends in the human genetics market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in genomic research. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of cutting-edge solutions and robust operational frameworks. ## Recent News & Developments Recent developments in the China Human Genetics Market have showcased significant advancements and shifts in the landscape. Huada Technology has continued to innovate in genetic sequencing technology, enhancing its capabilities that have subsequently drawn interest from various sectors. Fudan University is collaborating with biopharmaceutical firms to advance Research and Development in personalized medicine, reflecting a growth trend in tailored healthcare solutions. In terms of significant corporate activity, a notable merger occurred in May 2023 when the Beijing Genomics Institute acquired a majority stake in a biotech firm, thus reinforcing its position in the market. Additionally, growth in the valuation of companies like Novogene and Sangamo Therapeutics is impacting market dynamics, with Novogene reporting a substantial increase in revenue due to heightened demand for genetic testing services. Furthermore, WuXi AppTec is ramping up its biomanufacturing capabilities to meet the increasing need for gene therapies. Over the past 2-3 years, investment in genetic technologies has surged, particularly following government initiatives aimed at advancing life sciences and biotechnology sectors, further solidifying China's role as a leader in the global human genetics arena. ## Report Scope | MARKET SIZE 2024 | 2225.23(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2466.0(USD Million) | | MARKET SIZE 2035 | 6887.01(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.82% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), QIAGEN (DE), Myriad Genetics (US), BGI Genomics (CN), Genomatix (DE), PerkinElmer (US) | | Segments Covered | Application, Test | | Key Market Opportunities | Advancements in gene editing technologies create transformative opportunities in the human genetics market. | | Key Market Dynamics | Rapid advancements in gene editing technologies drive innovation and competition in the human genetics market. | | Countries Covered | China | ## Frequently Asked Questions **Q: What is the current valuation of the human genetics market in China as of 2024?** A: The overall market valuation was $2225.23 Million in 2024. **Q: What is the projected market valuation for the human genetics market in China by 2035?** A: The projected valuation for 2035 is $6887.01 Million. **Q: What is the expected CAGR for the human genetics market in China during the forecast period 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 10.82%. **Q: Which companies are considered key players in the human genetics market in China?** A: Key players include Illumina, Thermo Fisher Scientific, Roche, Agilent Technologies, QIAGEN, Myriad Genetics, BGI Genomics, Genomatix, and PerkinElmer. **Q: What are the main application segments of the human genetics market in China?** A: The main application segments include Wellness & E-Commerce, Preventive Medicine, and Diagnostic & Treatment. **Q: What was the market size for the Preventive Medicine segment in 2024?** A: The market size for the Preventive Medicine segment was $800.0 Million in 2024. **Q: How much is the Diagnostic & Treatment segment projected to grow by 2035?** A: The Diagnostic & Treatment segment is projected to grow to $3287.01 Million by 2035. **Q: What is the market size for NIPT in the human genetics market in China?** A: The market size for NIPT was $335.0 Million in 2024. **Q: What is the expected market size for Carrier Testing by 2035?** A: The expected market size for Carrier Testing is projected to reach $400.0 Million by 2035. **Q: How does the market for pharmacogenomic testing compare to other testing segments?** A: The market for pharmacogenomic testing was $300.0 Million in 2024, indicating a robust position among testing segments. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-human-genetics-market-49319*